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ir John Gurdon’s famous frog 
cloning experiments of the 1960s 
and ’70s answered a question that 
had been hanging over cell biologists 
since before the turn of the century: are 
the cells of an adult organism genetically 
identical to the fertilized egg from which 
they are derived? Briggs and King in the 
early ’50s suggested that cells’ genetic 
material is irreversibly altered as they 
begin to differentiate. But 
Gurdon showed that this 
was not the case. By trans-
ferring the nuclei of adult 
frog cells into enucleated 
eggs, he obtained cloned 
adult frogs (1, 2).
These experiments, to-
gether with the more recent 
cloning of Dolly the sheep, 
revealed the potential of 
nuclear transfer for cell 
replacement therapy. The 
potential would be even greater if cells 
could be reprogrammed directly, without 
the need to transfer nuclei into eggs—
a scant resource in humans. To this end, 
Gurdon has spent much of his career de-
ciphering the molecules and mechanisms 
that the egg uses to “rejuvenate” nuclei (3).
In 2006, Shinya Yamanaka from Kyoto 
University reported that adult fi  broblasts 
can be reprogrammed into embryonic 
stem cells by stably transducing them 
with four factors (4). In a recent interview, 
however, Gurdon explained that there is 
still much to be learned from nuclear 
transfer, as it remains the most effi  cient 
way to reprogram a nucleus.
FROM LATIN TO LABORATORY
I understand that at school you were 
strongly advised against becoming a 
scientist.
Yes indeed, that’s correct. I did one semes-
ter of biology, and then the master wrote a 
report that said, “I believe Gurdon has 
ideas about becoming a scientist. On pres-
ent showing, this is quite ridiculous. If he 
can’t learn simple biological facts he 
would have no chance of doing the work 
of a specialist, and it would be a sheer 
waste of time both on his part and of those 
who would have to teach him.” That was 
a pretty crippling introduction to biology.
You remember the report by heart?
I keep it above my desk for my amusement.
What made you deﬁ  ant enough to study 
science then?
As I was obviously deemed to be so bad at 
science, I applied to Oxford to do classics. 
But then the admissions tutor got in touch 
with me and said, “I’m delighted to tell you 
that we can accept you—on two conditions. 
One is that you start immediately. The 
second is that you do not study the subject 
in which you took the entrance exam.”
And so you opted for zoology?
Yes. Later in life, I happened to discover 
the person responsible for admissions. He 
told me that he’d made a mistake and was 
short of science students. He had 30 empty 
places in the college. So he’d gotten in 
touch with extra people, including myself. 
I was a bit lucky there.
My kind parents could see that I really 
was interested in biological sciences. So 
they arranged for me to have special 
teaching to make up for what I’d missed.
Clearly, it paid off, because you fell in 
love with the subject.
I always had been very interested in the 
subject. It was just that I couldn’t handle 
the teaching in school. The system didn’t 
suit me. We had no textbooks—this was 
after the war—and we had to remember 
facts and make notes. If you weren’t good 
at that, you couldn’t possibly pass any 
tests. And I wasn’t and didn’t.
But once you were at Oxford, you 
ﬂ  ourished and decided to stay on 
for a Ph.D.
Yes. But actually I fi  rst applied for a Ph.D. 
in entomology, which had been one of my 
hobbies, and they declined me. That was 
lucky for me, though, because instead a 
wonderful teacher in developmental biol-
ogy offered me a place. And that’s when 
things got underway.
That’s when you got paired up with 
Michael Fischberg and the nuclear 
transfer experiments began?
Yes, that’s right. Michael was my super-
visor. Wonderful man.
But after your Ph.D., despite all your 
success with nuclear transfer, you 
headed off to Caltech and studied 
something completely different. Why?
Michael said to me, “There’s no point in 
doing a postdoc in exactly the subject that 
you know how to do. You should do some-
thing completely different.” He happened 
to know George Beadle of Caltech, and 
through this connection, I was offered a 
postdoc position.
I worked with a very bright, young, 
new professor called Bob Edgar on bacterio-
phage. But I could never make these 
phage work properly, I couldn’t handle 
them at all. After a year of trying, I gave 
up and went back to working with em-
bryos, but with the great benefi  t of having 
had a year’s education at Caltech. It was 
good to take that year, and I now encour-
age my own students to consider doing 
something different for a while to give 
themselves a new point of view.
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John Gurdon isn’t giving up on nuclear transfer despite the developments 
in inducible pluripotency.
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RETURN OF THE NATIVE
Was it an easy decision to come back to 
England after Caltech?
It was a matter of amazing fortune. My old 
boss, Fischberg, accepted a professorship in 
Geneva, leaving his post empty, and the 
head of the department decided to offer 
me the position at a lower level. It suited 
me very well to come back to this country.
You moved to Cambridge in 1971, and 
then in 1989 you started the Wellcome/
CRC Institute. How did that come about?
I’d been at the Laboratory of Molecular 
Biology with Max Perutz for over ten 
years when Professor Horn at Cambridge 
University offered me and my colleague, 
Ron Laskey, a fl  oor to start up a molecular 
embryology unit.
That seemed to go well, and then the 
Cancer Research Campaign, who provided 
my funding, asked if we would be interested 
in expanding. We said, “Yes, that would 
be nice. Ideally we’d like to have a small 
research institute.” They said, “That’s good, 
but we can’t pay for all that.” But by good 
fortune, the Wellcome Trust was willing to 
collaborate with CRC to fund an institute.
In 2004, the institute was renamed 
after you. How did that feel?
That was an odd circumstance. When we 
started our institute, we called it the 
Wellcome/CRC Institute, and that was fi  ne, 
but then the same combination of sponsors 
started up other institutes around the coun-
try, also called Wellcome/CRC Institutes.
It was very diffi  cult to identify one from 
another. The view was that it would be better 
if we had a particular name to differentiate 
us. The director at the time was Jim Smith, a 
very fi  ne director, but there were so many 
Smiths in the world that it didn’t seem a very 
helpful name. So they looked down the list, 
and they saw a rare name, and thought, 
“Well, let’s take that one, that’ll do.”
It was a bit of luck. There’s no doubt 
about that. But if you’re wise, you grate-
fully accept it and take advantage of it.
CURRENT RESEARCH
Now that it’s possible to convert adult 
cells into embryonic stem cells using 
just four factors, where does that leave 
nuclear transfer?
Nuclear transfer is still the most effective 
way of deriving embryo cells from adult 
cells. The very clever Yamanaka approach 
works, but only about 1 in 5,000 cells will 
make the transition.
My own view is that the most success-
ful route would be to understand how it is 
that an egg can reprogram somatic cell 
nuclei with such high effi  ciency. An egg 
has a way of rejuvenating a nucleus that 
no other cell has. If we knew how the egg 
does it, we could combine that knowledge 
with the IPS (induced pluripotent stem 
cell) routes and make it more effi  cient.
This might also circumvent the need to 
add genes to cells, since there is some 
concern as to where the incoming genes 
land. If you can reprogram the nuclei the 
way the egg does, leaving the genome 
completely the same, that would be ideal.
I always thought nuclear transfer was 
terribly inefﬁ  cient.
To get a sexually mature adult animal this 
way is very ineffi  cient. For the purposes 
of therapeutic cell replacement, however, 
an adult animal is not what you want.
You’re trying to derive one kind of 
cell—a heart or brain cell—from another, 
easily accessible cell—a skin or bone 
marrow cell. And the effi  ciency with which 
an egg can cause a complete switch, such 
as from skin to muscle, 
is something like 30%, 
compared with 1 in 5,000 
for the IPS route. You 
would expect this, be-
cause every time an egg 
is fertilized, the sperm, 
which is a highly special-
ized cell, is turned back 
into an embryonic cell.
30% is pretty high. Is that in frogs?
That’s in frogs. But in mammals, assum-
ing you’re simply trying to derive one 
kind of cell from another—not trying to 
do an implantation—I would guess the 
effi  ciency is not that different.
So you think there’s more at work in 
the egg than the four factors that 
Yamanaka described?
I don’t quite know whether the egg makes 
use of those factors or not. People will 
soon fi  nd out. But it’s very unlikely that 
eggs use just those four gene products.
If not, then why are they capable, albeit 
inefﬁ  ciently, of converting cells back to 
a stem cell state?
Some people think that perhaps the fi  bro-
blasts go through a particular phase of the 
cell cycle in which they happen to be recep-
tive to the four Yamanaka factors. Others, 
including Yamanaka himself, think that 
maybe the four factors have to arrive in the 
cell at an exactly precise ratio. And when 
you transfect, you rarely achieve that.
We’ve been doing some work describing 
the histone states of genes during reprogram-
ming by nuclear transfer. It might be that by 
altering the histone state of genes that are the 
targets of the Yamanaka factors, we might 
make those genes more receptive and thus 
increase reprogramming effi  ciency.
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HeLa cell nuclei (top) appear quite different 
after being reprogrammed inside a frog 
egg (bottom).
“An egg has 
a way of 
rejuvenating 
a nucleus 
that no other 
cell has.”